Hyperinsulinism: Clinical Trials

197 trials for Hyperinsulinism, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

197 completed. 197 Phase 3, 54 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3197Completed 197
Phase 254Completed 54

Follow Hyperinsulinism: new trials by email Literature Review of Hyperinsulinism trials Research Report on Hyperinsulinism

Trials (filtered) newest first · largest first

All 197 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
mibavademab - Generalized Lipodystrophy
Phase 3CompletedRegeneron Pharmaceuticals92024-12-162026-07-29
Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye.
recombinant human insulin, Autologous serum - Dry Eye, Sjogren Syndrome
Phase 3CompletedInstituto de Oftalmología Fundación Conde de Valenciana252024-02-012026-08-27
Effect of Green Tea on Obese Pediatrics With Prediabetes
Green Tea Leaf Extract, Metformin Hydrochloride 500 MG - PreDiabetes
Phase 3CompletedAin Shams University902023-11-122026-11-12
Semaglutide 2.4 mg in Patients With Poor Weight-loss
Semaglutide 3 mg, Placebo - Obesity, Diabetes
Phase 3CompletedUniversity College, London702022-11-012026-10-26
Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care
Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy - Type 1 Diabetes, Diabetes Mellitus, Type 1
Phase 2 / Phase 3CompletedMcGill University Health Centre/Research Institute of the McGill University Health Centre282022-10-022025-01-22
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study
Muscle5 and TRIM7, Mixed exercise - Overweight, Obesity
Phase 3CompletedExerkine Corporation512022-08-152025-01-08
Afrezza® INHALE-1 Study in Pediatrics
Afrezza, Rapid-acting Insulin Analog, Basal Insulin - Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Phase 3CompletedMannkind Corporation3192021-09-292025-05-06
Antecedent Metabolic Health and Metformin Aging Study
Metformin, Placebo oral tablet - Aging, Insulin Sensitivity
Phase 3CompletedOklahoma Medical Research Foundation1662020-07-292026-11-05
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
dasiglucagon, Placebo - Congenital Hyperinsulinism
Phase 2 / Phase 3CompletedZealand Pharma122020-06-192025-03-14
ENAC Blockade and Arterial Stiffness
Placebo - Cap, Amiloride Pill - Overweight and Obesity, Insulin Resistance
Phase 2 / Phase 3CompletedUniversity of Missouri-Columbia1372019-07-152025-12-30
Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients
GP40071, NovoRapid® Penfill® - Diabetes, Diabetes Mellitus, Type 1
Phase 3CompletedGeropharm2642019-06-032020-07-23
Effects of Local Insulin on Varicose Ulcers for Wound Healing
Insulin Glargine, Saline - Chronic Venous Disease, Varicose Ulcer
Phase 3CompletedHospital Central "Dr. Ignacio Morones Prieto"132019-06-012020-03-17
The Bihormonal iLet Bionic Pancreas Feasibility Study
Bihormonal iLet Bionic Pancreas, Insulin-only Bionic Pancreas, Dasiglucagon - Type 1 Diabetes Mellitus
Phase 2 / Phase 3CompletedMassachusetts General Hospital122019-05-152019-12-16
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
Semaglutide 3mg and 7mg [Rybelsus], Weight loss diet - PCOS, Adolescent Obesity
Phase 2 / Phase 3CompletedUniversity of Colorado, Denver602019-05-032025-11-25
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
dasiglucagon - Congenital Hyperinsulinism
Phase 3CompletedZealand Pharma422019-05-022026-08-03
Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir
generic single tablet TAF/FTC/DTG - HIV
Phase 3CompletedThe HIV Netherlands Australia Thailand Research Collaboration1702019-05-012024-02-28
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira
IDegLira, insulin degludec, Metformin - Type 2 Diabetes Mellitus
Phase 3CompletedPopulation Health Research Institute1592019-04-232023-10-25
Amla on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
Amla, Placebo - Metabolic Syndrome
Phase 2 / Phase 3CompletedUniversity of Guadalajara282019-04-012022-11-08
A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
Dasiglucagon, Standard of Care - Congenital Hyperinsulinism
Phase 3CompletedZealand Pharma322019-02-072023-12-13
Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis
Propylthiouracil, Methimazole - Hyperthyroidism, Graves Disease
Phase 3CompletedUniversitas Indonesia362019-01-012021-11-12

Showing 20 of 197. Sign in to see all of them.

Narrower conditions

Insulin Resistance (123)  ·  Metabolic Syndrome (73)  ·  Diabetes Mellitus, Type 2 (47)  ·  Diabetes Mellitus (38)  ·  Obesity (32)  ·  Diabetes Mellitus, Type 1 (17)  ·  Glucose Intolerance (11)  ·  Hyperglycemia (11)  ·  Inflammation (10)  ·  Overweight (10)  ·  Cardiovascular Diseases (9)  ·  Hypertension (8)  ·  Dyslipidemias (7)  ·  Motor Activity (6)  ·  Prediabetic State (6)

Broader conditions

Nutritional and Metabolic Diseases (197)  ·  Glucose Metabolism Disorders (196)  ·  Metabolic Diseases (193)  ·  Endocrine System Diseases (97)  ·  Insulin Resistance (67)  ·  Pathological Conditions, Signs and Symptoms (56)  ·  Diabetes Mellitus (49)  ·  Signs and Symptoms (41)  ·  Body Weight (38)  ·  Nutrition Disorders (38)  ·  Overnutrition (37)  ·  Overweight (27)  ·  Pathologic Processes (25)  ·  Vascular Diseases (22)

Interventions

Metformin (23)  ·  Insulin (13)  ·  Insulin Glargine (10)  ·  Exercise (7)  ·  Rosiglitazone (5)  ·  3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine (4)  ·  Atorvastatin (4)  ·  Diet (4)  ·  dasiglucagon (4)  ·  salicylsalicylic acid (4)  ·  Biguanides (3)  ·  Cholecalciferol (3)  ·  Docosahexaenoic Acids (3)  ·  Insulin Aspart (3)  ·  Liraglutide (3)

Sponsors

AstraZeneca (5)  ·  Brigham and Women's Hospital (5)  ·  Tanabe Pharma Corporation (5)  ·  Ain Shams University (4)  ·  Geropharm (4)  ·  Population Health Research Institute (4)  ·  University of Colorado, Denver (4)  ·  Assistance Publique - Hôpitaux de Paris (3)  ·  Catalysis SL (3)  ·  Chinese Academy of Sciences (3)  ·  Joslin Diabetes Center (3)  ·  Massachusetts General Hospital (3)  ·  National Nutrition and Food Technology Institute (3)  ·  Sanofi (3)  ·  Sanwa Kagaku Kenkyusho Co., Ltd. (3)

Countries

United States (55)  ·  Canada (25)  ·  Germany (17)  ·  Italy (15)  ·  Mexico (14)  ·  United Kingdom (11)  ·  France (10)  ·  China (9)  ·  Japan (9)  ·  Australia (8)  ·  Russia (7)  ·  Denmark (6)  ·  Israel (6)  ·  Puerto Rico (6)  ·  Spain (6)

Top investigators

Kazuoki Kondo, MD (5)  ·  Takashi Kadowaki, Professor (4)  ·  Allison B. Goldfine, MD (3)  ·  Xu Lin, MD, PhD (3)  ·  David C Klonoff, M.D., F.A.C.P. (2)  ·  Dick C Chan, PhD (2)  ·  Francesco Squadrito, MD (2)  ·  Guillermo Umpierrez, MD (2)  ·  Hertzel Gerstein, MD (2)  ·  Kathleen Jablonski, PhD (2)  ·  Myrlene Staten, MD (2)  ·  Natalia McInnes, MD (2)

Results publications

PMID 20826632, PMID 31956422, PMID 32275191, PMID 37526194, PMID 11347758, PMID 12037147, PMID 1244564, PMID 14583175, PMID 15855569, PMID 16043738, PMID 16504835, PMID 16614616, PMID 16627388, PMID 16636217, PMID 16784922, PMID 17206944, PMID 17337495, PMID 17387446, PMID 17416370, PMID 17563348, PMID 17583798, PMID 18406632, PMID 18509206, PMID 18671796, PMID 19092145, PMID 19116237, PMID 19156626, PMID 19321570, PMID 19655124, PMID 19720420, PMID 19726779, PMID 19898642, PMID 20019677, PMID 20092585, PMID 20231565, PMID 20484482, PMID 20573639, PMID 20671408, PMID 20807873, PMID 20956707, PMID 21059830, PMID 21164548, PMID 21270268, PMID 21444887, PMID 21473976, PMID 21742107, PMID 21768545, PMID 21775749, PMID 21795429, PMID 21832112

NIH funding

2005 (2), U01DK074556 (2), 1RC1DK086132 (1), 2008 (1), 2009 (1), 2015 (1), 2017 (1), 5UL1TR000135 (1), F32DK068902 (1), KL2TR000136 (1), P50CA098258 (1), P50HL083813 (1), R01AG018198 (1), R01AG020076 (1), R01AG064951 (1)